Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-872 (GSK2399872A) 是一种有效且特异性的 RIP3 激酶抑制剂,降低 RIPK3 介导的坏死和随后的 HMGB1 的细胞质易位和表达,可改善早期脑损伤中的脑水肿和神经功能缺损。它以高亲和力结合 RIP3 激酶结构域,IC50为1.8 nM,并抑制激酶活性,IC50为1.3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 282 | 现货 | ||
2 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 713 | 现货 | ||
10 mg | ¥ 1,150 | 现货 | ||
25 mg | ¥ 2,230 | 现货 | ||
50 mg | ¥ 3,390 | 现货 | ||
100 mg | ¥ 4,920 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 727 | 现货 |
产品描述 | GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM). |
靶点活性 | RIP3K:1.8 nM |
体外活性 | GSK872 (1 μM) has no inhibition for most of 300 human protein kinases tested. It fails to inhibit RIP1 kinase. In HT-29 cells, GSK872 concentration-dependently blocks TNF-induced necroptosis. In cell-based assays, there is a 100- to 1000-fold shift in the IC50 compared to the cell-free biochemical assays. GSK872 inhibits DAI- or TLR3-induced (RIP1-independent) death. It induces caspase activation and then induces apoptotic cell death[1]. |
体内活性 | In compared with no treatment after ischemic injury in vivo, GSK872 can significantly reduce HIF-1α expression [3]. |
别名 | GSK872, GSK'872, GSK2399872A |
分子量 | 383.49 |
分子式 | C19H17N3O2S2 |
CAS No. | 1346546-69-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 71 mg/mL (185.1 mM)
Ethanol: 38 mg/mL (99.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.6076 mL | 13.0381 mL | 26.0763 mL | 65.1907 mL |
5 mM | 0.5215 mL | 2.6076 mL | 5.2153 mL | 13.0381 mL | |
10 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL | 6.5191 mL | |
20 mM | 0.1304 mL | 0.6519 mL | 1.3038 mL | 3.2595 mL | |
50 mM | 0.0522 mL | 0.2608 mL | 0.5215 mL | 1.3038 mL | |
DMSO | 100 mM | 0.0261 mL | 0.1304 mL | 0.2608 mL | 0.6519 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK-872 1346546-69-7 Apoptosis NF-Κb RIP kinase translocation neurological HMGB1 Receptor-interacting protein kinases brain GSK872 GSK 872 cytoplasmic deficits Inhibitor GSK'872 edema inhibit RIPK GSK2399872A inhibitor